Features & Benefits
- The HCV IRES sequence is highly conserved across HCV genotypes, and
targeted inhibitors are expected to be broadly effective and display relatively
- Lead compound potency is in the low micromolar range. The team
is continuing identification and optimization of potential leads.
- Compounds show good in vivo activity in a number of cell culture systems,
with minimal toxicity.
Hepatitis C is a global health
concern, with over 150 million people infected worldwide. It is the
leading cause of liver transplantation and liver cancer. Current
treatments are lacking in effectiveness. Novel approaches to
treatment could capture a large part of the global market, which is projected to
reach $12B in the US by 2015.
Provisional patent applications are
Dr. Darrell Davis, Department of Medicinal
Chemistry and Dr. Curt Hagedorn, Internal Medicine.